Certara said this week that Medivir, a Swedish pharmaceutical company that focuses on infectious diseases such as hepatitis C, has selected its D360 software as its global drug discovery platform.

According to Certara, Medivir will use D360 — an integrated solution for querying, analyzing, and visualizing drug discovery data — to deliver chemical structure and biological assay data and analytic tools to its discovery chemists and biologists based in Stockholm and Cambridge, UK.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."